Companies: 10,795·Total market cap: $144.5T

Apimeds Pharmaceuticals US, Inc

Apimeds Pharmaceuticals US, Inc

APUSAMEXHealthcare● Active

$1.13

$-0.15(-11.71%)

Market Cap$1421211

P/E Ratio—

52W High$40.31

52W Low$1.17

Avg Volume132K

Open$1.10

Beta-1.03

Net Income Financials Revenue

Apimeds Pharmaceuticals US, Inc (APUS) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

APUS · net income · updated Jun 9, 2026

Core profitability metrics

APUS · net income · margin · TTM · CAGR

Net income was −$6.0M for FY2025 (fiscal year ending 2025-12-31), down 331.7% year-over-year. Net profit margin was —.

FY2025 Net Income−$6.0M▼ -331.7% YoY

Trailing 12M (TTM)−$40.7Mtrailing 4 quarters sum

Net Profit Margin——

YoY Change-331.7%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · APUS net income history · APUS profit margin

Annual net income data

APUS · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$6.0M▼ 331.7%—$0

FY2024Loss−$1.4M▼ 78.7%—$0

FY2023Loss−$777,694▼ 16.3%—$0

FY2022Loss−$668,666▲ +34.8%—$0

FY2021Loss−$1.0M——$0

Net income vs peers (Healthcare)

APUS vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

#1

Apimeds Pharmaceuticals US, IncYOU

APUS

−$6.0M-331.7%—

Loss

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Apimeds Pharmaceuticals US, Inc (APUS) reported net income of −$6.0M for FY2025 (fiscal year ending 2025-12-31), down 331.7% year-over-year. The net profit margin was — — meaning the company kept $— of every dollar of revenue as profit.

Apimeds Pharmaceuticals US, Inc has not yet achieved annual profitability based on available data (5 fiscal years). The company has reported net losses across all available periods.

Apimeds Pharmaceuticals US, Inc's net profit margin was — for FY2025, based on the latest annual results.

Investors sometimes search for "Apimeds Pharmaceuticals US, Inc net worth" — the company's market capitalization is a separate figure from APUS net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

APUS net income · 4 questions

Apimeds Pharmaceuticals US, Inc is not currently profitable on an annual basis. The company reported a net loss of $6.0M for FY2025.

is APUS profitabledoes APUS make a profitAPUS profitabilityAPUS profitable company

▸ Source: FMP /income-statement · GAAP · Apimeds Pharmaceuticals US, Inc · Apimeds Pharmaceuticals US, Inc SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026